HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Israel's Kinoko Targets US With Nutrition Bars, Meat Alternatives From Mushroom-Based Fermentation

Executive Summary

Kinoko’s unprocessed superfood is competitively priced to tofu and easily scalable. Market-ready products also allow for manufacturing sustainability, with minimal use of water and electricity, plus reduced emissions.

You may also be interested in...



Vagisil Marketer Combe Enters Personal Lubricant Market With BioFilm Acquisition

Vagisil and BioFilm’s Astroglide “demonstrate very high levels of brand awareness, brand loyalty, and repeat purchase, and continue to attract new and younger consumers into the category,” firms say.

US Health And Wellness Launches: Perrigo, Lightbody, Nature’s Bounty, PLT, Healthycell, More

Nicotine mint lozenge approval for Perrigo; Lightbody for digital vision health; PLT has broad-spectrum immune health ingredient; Souvenaid for stronger synapses; Kinesiology tape for cellular oxygenation; Healthycell joint health and mobility gel; Nature’s Bounty Optimal Solutions hair, metabolism supplements; and Perricone extends vitamin c ester line.

US Dietary Ingredient ‘Preclusion’ Swings On Information Closed To Supplement Industry – CRN

Trade group contends FDA’s misuse of regulation prohibiting any substance studied or approved as a drug in US from being used as dietary ingredients undermines innovation in supplement industry and is detrimental to consumer choice and health.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel